These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24246787)

  • 1. Calibration of quality-adjusted life years for oncology clinical trials.
    Sloan JA; Sargent DJ; Novotny PJ; Decker PA; Marks RS; Nelson H
    J Pain Symptom Manage; 2014 Jun; 47(6):1091-1099.e3. PubMed ID: 24246787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
    Radice D; Redaelli A
    Pharmacoeconomics; 2005; 23(1):69-75. PubMed ID: 15693729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1).
    Sloan JA; Bonner JA; Hillman SL; Allmer C; Shanahan TG; Brooks BJ; Marks RS; Vargas-Chanes D; Jett JR
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):371-81. PubMed ID: 11872282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating mortality and morbidity outcomes: using quality-adjusted life years in critical care trials.
    Ferguson ND; Scales DC; Pinto R; Wilcox ME; Cook DJ; Guyatt GH; Schünemann HJ; Marshall JC; Herridge MS; Meade MO;
    Am J Respir Crit Care Med; 2013 Feb; 187(3):256-61. PubMed ID: 23204250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.
    Marino P; Roché H; Moatti JP;
    Am J Clin Oncol; 2008 Apr; 31(2):117-24. PubMed ID: 18391594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data.
    Revicki DA; Feeny D; Hunt TL; Cole BF
    Qual Life Res; 2006 Apr; 15(3):411-23. PubMed ID: 16547779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.
    Adi Y; Juarez-Garcia A; Wang D; Jowett S; Frew E; Day E; Bayliss S; Roberts T; Burls A
    Health Technol Assess; 2007 Feb; 11(6):iii-iv, 1-85. PubMed ID: 17280624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology.
    Solem CT; Kwon Y; Shah RM; Aly A; Botteman MF
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):245-253. PubMed ID: 29402128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
    Marino P; Sfumato P; Joly F; Fizazi K; Oudard S; Culine S; Habibian M; Boher JM; Gravis G
    Eur J Cancer; 2017 Oct; 84():27-33. PubMed ID: 28780479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.